论文部分内容阅读
新抗生素Isepamicin(ISP),即1-N-羟基-氨基-丙酰-庆大霉素B,是由庆大霉素B半合成的新的氨基糖苷类抗生素(AGS),由美国先令公司于1984年试制成功,后转由日本东洋酿造等公司开发。 Isepamicin的化学结构与由卡那霉素A(KM)半合成的丁胺卡那霉素(AMK)相似。已确认ISP有比AMK更高的抗菌活性;在肾脏毒性和听觉毒性上比AMK更低,使用安全性更高;耐药菌比AMK更少,ISP不仅对庆大霉素(GM)耐药菌有效,且对AMK耐药菌有效;在临床上以AMK为对照,经双盲比较试验,不仅确认在呼吸道感染和复杂性尿路感染上ISP的临床实用性,而且证实
The new antibiotic Isepamicin (ISP), 1-N-hydroxy-amino-propionyl-gentamicin B, is a new aminoglycoside antibiotic (AGS) semisynthetic by gentamicin B, In 1984 trial success, after the transfer by the Japanese Toyo brewing and other companies to develop. The chemical structure of Isepamicin is similar to amikacin (AMK) semi-synthesized by kanamycin A (KM). It has been confirmed that ISPs have higher antibacterial activity than AMK, lower renal toxicity and auditory toxicity than AMK, higher safety of use, less resistant bacteria than AMK, ISP not only resistant to gentamicin (GM) Effective for AMK resistant bacteria; AMK as a control in clinical trials, double-blind comparison test not only confirms the clinical utility of ISP in respiratory tract infections and complicated urinary tract infections, but also confirmed